Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track QNTM with free AI briefings, catalyst countdowns, and dilution alerts.

QNTM · Quantum Biopharma Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.9M Cash on Hand
8.4mo Cash Runway
Follow QNTM by email Get an email when QNTM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about QNTM, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
dermo cosmetic product Hypotrichosis Phase 4 · NCT07776028 Completed
Firibastat Hypertension Phase 3 · NCT04277884 Completed
Firibastat (QGC001) Period 1 Hypertension (HTN) Phase 3 · NCT04857840 Terminated
Dendritic Cell Vaccination Breast Cancer Phase 1/2 · NCT00879489 Unknown
Ultra-micronized Palmitoyl Ethylamine (PEA)… Mast Cell Activation Syndrome Phase 2 · NCT05652907 Terminated
QGC001 Hypertension Phase 2 · NCT03198793 Completed
Lucid-21-302 Healthy Participants Phase 1 · NCT05821387 Completed
QGC001 [(3S,3'S)-4,4'-dithiobis… Essential Hypertension Phase 1 · NCT01900184 Completed

Also used in these trials (approved or third-party drugs, not QNTM's own candidates): Ramipril.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

QNTM holds $3.9M in cash and short-term investments and burns about $1.4M/quarter from operations, an estimated runway of 8.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when QNTM files for a raise →

👥 Who Owns QNTM

Insiders Form 4 data not loaded yet Institutions 100% Public and other holders 0%
HolderTypeShares% of sharesAs of
Malone Wealth Ventures LLC Institution (13G, 5%+) 375,752 3,131,266.67% 2026-02-03

Share count 12 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full QNTM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QNTM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.